William Conkling - 27 Feb 2025 Form 4 Insider Report for Cyclo Therapeutics, Inc. (CYTH)

Reporting relationship: Director
Issuer ticker: CYTH
Reported as of: 27 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Mar 2025, 11:45:25 UTC
Prior SEC filing: 15 Jan 2025
Next SEC filing: 25 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ William Conkling

Key filing fact

William Conkling filed Form 4 for Cyclo Therapeutics, Inc. (CYTH) on 03 Mar 2025.

Key facts

This page summarizes William Conkling's Form 4 filing for Cyclo Therapeutics, Inc. (CYTH).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Mar 2025, 11:45.

Change

Previous filing in this sequence was filed on 15 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CYTH transaction

Common Stock

Award

Transaction value: $0
Shares: +27,654
Change %: +55%
Price: $0.000000
Shares after: 77,884
Date: 27 Feb 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the fourth quarter of 2024 and from January 1, 2025 through March 25, 2025. The number of shares received in lieu of cash was calculated based on the closing price of $0.77 per share of common stock on February 26, 2025.